PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.
PDS Biotechnology is changing its main focus to work on a cancer medicine instead of its other projects. When a company shifts direction like this, watch to see if the new plan actually works—that will tell you if the move was smart or risky.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.